Dose Insider / Glossary / Non-peptide GLP-1

Non-peptide GLP-1 agonistWhat it is and why it matters

Updated November 20, 2026 路 3 min read 路 FOUNDAYO, WEGOVY, RYBELSUS labels; NEJM 2023 and 2025

A non-peptide GLP-1 agonist is a medicine that activates the GLP-1 receptor without being a peptide, the chain of amino acids that every earlier GLP-1 drug is built from. It is a small molecule, closer in size to an ordinary pill drug, and it can be absorbed from the gut far better than a peptide.

77%Orforglipron, 0.8 mg, share of a pill absorbed
Share of a pill absorbedAbsolute bioavailability, from the labelsOrforglipron, 0.8 mg77%Ozempic and Wegovy tablets1% to 2%Rybelsus0.4% to 1%Share of a pill absorbedAbsolute bioavailability, from the labelsOrforglipron, 0.8 mg77%Ozempic and Wegovy tablets1% to 2%Rybelsus0.4% to 1%

Peptide tablets need fasting and a 30-minute wait; orforglipron does not.

On this page

Orforglipron, sold as Foundayo since its U.S. approval in 2026, is the one with a U.S. label; about 77% of a dose reaches the blood, against 1% to 2% for the semaglutide tablets.1,2,3

The problem with peptides

The body's own GLP-1 is a peptide, and so are the medicines modeled on it: exenatide, liraglutide, dulaglutide, semaglutide and tirzepatide. Peptides are large; semaglutide's molecular weight is 4,113.58.4 They are also poorly absorbed from the gut. That is why most are injected, and why the semaglutide tablets need an absorption enhancer, SNAC, and strict rules. They are taken on an empty stomach in the morning with no more than 4 ounces of plain water, and nothing else goes in by mouth for at least 30 minutes. Even so, only 0.4% to 1% of a Rybelsus tablet and 1% to 2% of an Ozempic or Wegovy tablet is absorbed.2,3

The small-molecule way

Orforglipron's phase 2 report calls it a nonpeptide GLP-1 receptor agonist, and its phase 3 report an oral small-molecule one.5,6 Its molecular weight is 902.0, less than a quarter of semaglutide's. On the Foundayo label:1

The last point is the trade-off. Peptides such as semaglutide are cleared by breaking down the protein chain, while a small molecule handled by a liver enzyme can interact with other drugs that use the same enzyme. With a strong CYP3A4 inhibitor, the Foundayo label caps the dose at 9 mg a day.1

Results so far

In the phase 2 trial, 272 adults lost 9.4% to 14.7% of their weight at week 36, against 2.3% on placebo.5 In ATTAIN-1, a 72-week trial in 3,127 adults with obesity, weight fell by up to 11.2%, against 2.1% on placebo.6 In adults with type 2 diabetes the label reports up to 9.6%, against 2.5%.1 The Wegovy 25 mg tablet, a peptide, lowered weight by 13.6% at week 64 in its own trial.3 The two were not compared directly, and the trials differ, so the gap is a rough guide. What the small molecule changes most is the routine of taking it.

The daily routine

The rules for a missed tablet show the difference in practice. A missed Rybelsus or Ozempic tablet is skipped and the next one taken the following day, because each must be taken fasting in the morning.2 A missed Foundayo tablet is taken as soon as possible, without doubling the next one; only after 7 or more missed days does the climb restart lower.1

What stays the same

A different molecule acting on the same receptor brings the same class effects. On the Foundayo label, nausea was reported by up to 35% against 10% on placebo, and the drug carries the same boxed warning about thyroid C-cell tumors seen in rodents as the injected medicines.1 Our page on nausea on a GLP-1 covers what helps.

Sources

  1. FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company; DailyMed, version published August 13, 2026; boxed warning and sections 2, 6.1, 7, 11 and 12. dailymed.nlm.nih.gov
  2. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, version published August 19, 2026; sections 2 and 12.3. dailymed.nlm.nih.gov
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 12.3 and 14. accessdata.fda.gov
  4. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 11. accessdata.fda.gov
  5. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 2023;389:877-888. doi:10.1056/NEJMoa2302392
  6. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. doi:10.1056/NEJMoa2511774

Related analyses

Log each tablet and see your doses, weight and symptoms together.

Open Dose Insider